Peptides
PT-141 (Bremelanotide)
PT-141 (Bremelanotide) is a melanocortin receptor agonist studied in libido research. Below, we compare vendors currently stocking research-grade PT-141 — not just a single sales page.
PT-141 (Bremelanotide) is a melanocortin receptor agonist studied in libido research. Below, we compare vendors currently stocking research-grade PT-141 — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 SwissChemsBest Value |
$49.99 – $499.90 | Third-party COA | Buy Here → | |
 Amino Vault |
$51.85 – $163.20 | Third-party COA | Buy Here → | |
 American Peptides |
$60.00 | Third-party COA | Buy Here → |
PT-141 (Bremelanotide) is a synthetic peptide and melanocortin receptor agonist. It holds FDA approval under the brand name Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of the better-documented peptides in this category.
Research-grade Bremelanotide is typically supplied as a lyophilized powder in sealed vials, commonly at 10mg strength, intended for laboratory research use; the FDA-approved Vyleesi product is a separate, prescription-only autoinjector formulation.
PT-141 acts as an agonist at melanocortin 4 receptors (MC4R) in the central nervous system, a pathway distinct from the vascular mechanism used by PDE5 inhibitors such as sildenafil, which is why it has been studied specifically for centrally-mediated sexual arousal research.
PT-141's approved indication is grounded in Phase 3 clinical trials studying its effects on sexual desire in women, and it remains the primary reference compound for melanocortin-pathway research in this area.
Beyond its approved use, PT-141 is studied more broadly as a research tool for examining MC4R signaling, an area that overlaps with appetite and energy-balance research given MC4R's role in those pathways.
In its FDA-approved clinical use, documented side effects include nausea, flushing, headache, and transient increases in blood pressure, detailed in the Vyleesi prescribing information. Research-grade material sourced outside that regulated supply chain has not undergone the same quality controls.
The FDA-approved clinical dose for Vyleesi is 1.75mg by subcutaneous autoinjector, administered as needed at least 45 minutes before anticipated activity, per its prescribing information — this reflects the approved clinical protocol, not a recommendation for use of unregulated research material.
Compound X does not sell PT-141 (Bremelanotide) directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
PT-141/Bremelanotide's clinical trial data and prescribing information are available via the FDA and are also indexed on PubMed under "Bremelanotide melanocortin receptor."
New guides, vendor comparisons and compound breakdowns every week.